Cyclerion Therapeutics, Inc. (NASDAQ:KRSA) Sees Significant Increase in Short Interest

Posted by Brian Himes on Oct 31st, 2026

Cyclerion Therapeutics, Inc. (NASDAQ:KRSA – Get Free Report) was the recipient of a large increase in short interest during the month of October. As of October 15th, there was short interest totaling 23,804 shares, an increase of 106.1% from the September 30th total of 11,552 shares. Based on an average daily volume of 97,778 shares, the days-to-cover ratio is presently 0.2 days. Approximately 0.1% of the shares of the stock are short sold.

Wall Street Analyst Weigh In

A number of equities analysts have commented on KRSA shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Cyclerion Therapeutics in a research note on Friday, July 24th. Guggenheim began coverage on shares of Cyclerion Therapeutics in a research report on Monday, September 28th. They set a “buy” rating and a $70.00 price target on the stock. Wedbush started coverage on shares of Cyclerion Therapeutics in a report on Monday, October 5th. They set an “outperform” rating and a $44.00 price objective on the stock. TD Cowen started coverage on shares of Cyclerion Therapeutics in a research report on Monday, September 14th. They issued a “buy” rating for the company. Finally, Stifel Nicolaus started coverage on shares of Cyclerion Therapeutics in a research note on Monday, September 14th. They issued a “buy” rating and a $43.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $53.00.

Get Our Latest Stock Analysis on Cyclerion Therapeutics

Cyclerion Therapeutics Stock Performance

KRSA traded down $0.08 during mid-day trading on Friday, reaching $30.14. The stock had a trading volume of 104,184 shares, compared to its average volume of 147,471. The firm has a market capitalization of $1.37 billion, a price-to-earnings ratio of -2.59 and a beta of 1.72. Cyclerion Therapeutics has a 52 week low of $7.19 and a 52 week high of $59.36.

Hedge Funds Weigh In On Cyclerion Therapeutics

Several hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. bought a new stake in Cyclerion Therapeutics during the 2nd quarter worth about $57,000. Braidwell LP bought a new position in shares of Cyclerion Therapeutics in the 2nd quarter valued at about $532,000. Finally, ADAR1 Capital Management LLC bought a new position in shares of Cyclerion Therapeutics in the 2nd quarter valued at about $1,013,000. Institutional investors own 75.62% of the company’s stock.

About Cyclerion Therapeutics

(Get Free Report)

Cyclerion Therapeutics, Inc was a clinical-stage biopharmaceutical company focused on developing medicines for serious central nervous system and cardiopulmonary diseases. The company’s research centered on soluble guanylate cyclase (sGC) stimulators, a class of compounds intended to regulate cellular signaling and potentially address diseases associated with impaired nitric oxide signaling.

Cyclerion was formed in 2019 as a spin-off from Ironwood Pharmaceuticals. Its historical development portfolio included olinciguat, an investigational treatment studied for sickle cell disease, and praliciguat, which was evaluated for conditions including diabetic nephropathy and nonalcoholic steatohepatitis.